Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
IPCA LABS TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IPCA LABS Mar-23 |
TEVA PHARMA Dec-13 |
IPCA LABS/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,062 | 3,486 | - | |
Low | Rs | 768 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 243.0 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 19.4 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 29.7 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 109.40 | - | |
Avg Dividend yield | % | 0.4 | 3.4 | 13.0% | |
Book value per share (Unadj.) | Rs | 230.3 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 253.70 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.8 | 1.6 | 231.3% | |
Avg P/E ratio | x | 47.2 | 26.1 | 181.1% | |
P/CF ratio (eoy) | x | 30.8 | 11.4 | 271.2% | |
Price / Book Value ratio | x | 4.0 | 1.5 | 271.1% | |
Dividend payout | % | 20.6 | 87.5 | 23.6% | |
Avg Mkt Cap | Rs m | 232,120 | 2,761,843 | 8.4% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 12,876 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 61,642 | 1,696,422 | 3.6% | |
Other income | Rs m | 1,518 | 0 | - | |
Total revenues | Rs m | 63,160 | 1,696,422 | 3.7% | |
Gross profit | Rs m | 9,033 | 464,566 | 1.9% | |
Depreciation | Rs m | 2,616 | 137,123 | 1.9% | |
Interest | Rs m | 482 | 33,320 | 1.4% | |
Profit before tax | Rs m | 7,453 | 294,122 | 2.5% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 2,534 | -3,591 | -70.6% | |
Profit after tax | Rs m | 4,919 | 105,974 | 4.6% | |
Gross profit margin | % | 14.7 | 27.4 | 53.5% | |
Effective tax rate | % | 34.0 | -1.2 | -2,784.4% | |
Net profit margin | % | 8.0 | 6.2 | 127.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 51,893 | 1,145,757 | 4.5% | |
Current liabilities | Rs m | 18,058 | 999,197 | 1.8% | |
Net working cap to sales | % | 54.9 | 8.6 | 635.3% | |
Current ratio | x | 2.9 | 1.1 | 250.6% | |
Inventory Days | Days | 51 | 91 | 56.4% | |
Debtors Days | Days | 6 | 96 | 6.1% | |
Net fixed assets | Rs m | 34,336 | 554,089 | 6.2% | |
Share capital | Rs m | 254 | 4,176 | 6.1% | |
Net worth | Rs m | 58,420 | 1,884,403 | 3.1% | |
Long term debt | Rs m | 6,518 | 867,418 | 0.8% | |
Total assets | Rs m | 86,229 | 3,876,868 | 2.2% | |
Interest coverage | x | 16.5 | 9.8 | 167.6% | |
Debt to equity ratio | x | 0.1 | 0.5 | 24.2% | |
Sales to assets ratio | x | 0.7 | 0.4 | 163.4% | |
Return on assets | % | 6.3 | 3.6 | 174.3% | |
Return on equity | % | 8.4 | 5.6 | 149.7% | |
Return on capital | % | 12.2 | 4.9 | 247.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,058 | 270,322 | 3.0% | |
From Investments | Rs m | -7,250 | -95,786 | 7.6% | |
From Financial Activity | Rs m | 5,072 | -324,269 | -1.6% | |
Net Cashflow | Rs m | 5,881 | -149,733 | -3.9% |
Compare IPCA LABS With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare IPCA LABS With: ROOPA INDUSTRIES LYKA LABS GUJ.TERC LAB MESCO PHARMA TYCHE INDUSTRIES
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.